2026 Annual Meeting | C48 - Myelin Oligodendrocyte Glycoprotein Antibody Disorders (MOGAD)

Date Sunday 04/19/26

Time 07:00 AM - 09:00 AM CDT Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program will be available in the meeting's On Demand product.

Event Type Seminar

Director(s) Giulia Fadda, MD

Topic(s) Multiple Sclerosis

Learning Objectives Participants will learn to apply the MOGAD diagnostic criteria and recognize their strengths and limitations as observed in real-world practice; identify the typical MOGAD clinical course and the tools for poor-outcome risk stratification; and integrate emerging evidence to guide both acute and long-term relapse-prevention strategies, with a focus on immunotherapies under active clinical investigation.

CME Available 2.00 CME credits

Core Competencies Patient Care & Procedural Skills, Medical Knowledge

Program Level Intermediate

Recommended Audience Fellow, Resident, General Neurologist, Specialist Neurologist, Advanced Practice Provider, Medical Student

Teaching Styles Didactic, Audience Participation

Event Timeline
07:00 AM - 07:35 AM CDT	Speaker	Recognizing MOGAD: Clinical Features and Diagnostic Approach Giulia Fadda, MD
07:35 AM - 08:10 AM CDT	Speaker	Predicting Outcomes in MOGAD
08:10 AM - 09:45 AM CDT	Speaker	Evolving Insights into Treatment Strategies Michael Levy, MD, PhD, FAAN

Faculty Disclosures
Giulia Fadda, MD	Dr. Fadda has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amgen/Horizon Therapeutics. Dr. Fadda has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for roche. Dr. Fadda has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Fadda has received personal compensation in the range of $500-$4,999 for serving as a Speaker with Novartis.
Michael Levy, MD, PhD, FAAN	Dr. Levy has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Mitsubishi Pharma. Dr. Levy has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB Pharma. Dr. Levy has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi. Dr. Levy has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Levy has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon. Dr. Levy has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Levy has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier. Dr. Levy has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Various law firms. The institution of Dr. Levy has received research support from National Institutes Health.
	No disclosure on file

��ɫ��

��ɫ��